

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**In the claims**

Claims 1-27 (cancelled)

Claim 28 (previously presented): A purified analog of a T cell-dependent immunogen implicated in an antibody-mediated pathology, said analog comprising an epitope that binds specifically to an antibody to which the immunogen binds specifically, wherein the analog lacks T cell epitopes capable of activating T cells in an individual having the antibody-mediated pathology, and wherein the analog is a polypeptide.

Claim 29 (previously presented): The analog of claim 28, further comprising a functional group for coupling to a carrier.

Claim 30-31 (cancelled)

Claim 32 (previously presented): A complex comprising the analog of claim 28 bound to an antibody to which the immunogen binds specifically.

Claim 33-37 (cancelled)

Claim 38 (previously presented): A purified analog of a T cell-dependent immunogen implicated in an antibody-mediated pathology, said analog comprising an epitope that binds specifically to an antibody to which the immunogen binds specifically in an individual having the antibody-mediated pathology, wherein the analog has a T cell stimulation index below about 2-3 above background, and wherein the analog is a polypeptide.

Claim 39 (previously presented): The analog of claim 38, wherein the analog has a T cell stimulation index below about 1-2 above background.

Claim 40 (previously presented): The analog of claim 38, further comprising a functional group for coupling to a carrier.

Claim 41-42 (cancelled)

Claim 43 (previously presented): A complex comprising the analog of claim 38 bound to an antibody to which the immunogen binds specifically.

Claim 44 (previously presented): The analog of claim 28, wherein the immunogen is an external immunogen.

Claim 45 (previously presented): The analog of claim 44, wherein the external immunogen is a biological drug, allergen or a D immunogen associated with Rh hemolytic disease.

Claim 46 (previously presented): The analog of claim 28, wherein the immunogen is a self-immunogen.

Claim 47 (previously presented): The analog of claim 46, wherein the self-immunogen is that associated with thyroiditis, diabetes, stroke, male infertility, myasthenia gravis, or rheumatic fever